PMID-19289567 – Ipamorelin in Rodent Postoperative Ileus Model
Venkova K, Fraser G, Hoveyda HR, Bhatt DK, Greenwood-Van Meerveld B. Prokinetic effects of a new ghrelin receptor agonist TZP-101 in a rat model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110-1116.
Quick Reference
| Property | Value |
|---|---|
| PMID | 19289567 |
| DOI | 10.1124/jpet.108.149211 |
| Year | 2009 |
| Journal | Journal of Pharmacology and Experimental Therapeutics |
| Study Type | Animal in vivo |
| Evidence Level | V |
| Sample | Rats with surgically induced postoperative ileus |
| Peptide(s) Studied | Ipamorelin |
Key Findings
- Repeated IV administration of ipamorelin improved GI recovery in a rat postoperative ileus model
- Treated animals showed increased fecal output compared to vehicle controls, indicating restored bowel motility
- Food consumption was increased in the ipamorelin group, reflecting improved GI tolerance
- Body weight gain was greater in treated animals, suggesting improved nutritional recovery
- The prokinetic effect was mediated through GHS-R1a (ghrelin receptor) activation in the enteric nervous system
- Results provided the preclinical rationale that led directly to the Phase II human clinical trial (PMID-25331030)
Study Design
Rats underwent abdominal surgery to induce postoperative ileus. Beginning postoperatively, animals received repeated IV injections of ipamorelin or vehicle control. GI recovery was assessed by measuring fecal output (pellet count and weight), food intake, and body weight over the recovery period. The timing and duration of prokinetic effects were characterized.
Limitations
- Rat GI physiology differs from human in transit times and motility patterns
- Surgically induced ileus model may not fully replicate the complexity of human postoperative ileus
- IV route used — no data on subcutaneous or oral administration
- Single dose level tested
- No assessment of GH secretion — focused entirely on GI prokinetic effects
- Short observation period
Clinical Relevance
This preclinical study established ipamorelin's GI prokinetic properties as distinct from its GH-releasing effects. This dual functionality is clinically valuable: patients receiving ipamorelin for GH optimization may also benefit from improved gut motility, particularly relevant in protocols where other peptides (e.g., BPC-157, KPV) target GI healing. The study also directly led to the Phase II RCT in surgical patients, creating a translational bridge from bench to bedside.
Related
#research #animal-in-vivo #ipamorelin #evidence-level-V